BIO-PREDISC-TIA SWISS Cohort Study
PREDISC
BIOmarkers and PREDISC Diagnostic Evaluation for Patients With Suspected Transient Ischemic Attacks: the BIOPREDISC- TIA SWISS Cohort Study
1 other identifier
observational
64
1 country
2
Brief Summary
This research project aims at contributing to improve TIA diagnosis and management by using PREDISC scores and specific biomarkers thought to have elevated levels in TIA patients. A swift and accurate TIA diagnosis allows starting treatment of the patient adequately and shortly after the event. The shorter the time between the event and treatment onset, the better the outcome. This approach will be an important step forward in TIA diagnosis and management, similarly to acute coronary syndrome as discussed above.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Aug 2017
Longer than P75 for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 4, 2017
CompletedFirst Submitted
Initial submission to the registry
June 19, 2019
CompletedFirst Posted
Study publicly available on registry
June 21, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2021
CompletedApril 18, 2024
April 1, 2024
3.4 years
June 19, 2019
April 16, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Levels of specific biomarkers (Platelet Basic Protein (PBP), ceruloplasmin, microRNAs, exosomal particles) in patients with suspected TIA.
Diagnostic performance according to PREDISC scale
1 year
Eligibility Criteria
Patients with suspected TIA (defined as the acute onset of focal neurological symptoms lasting \<24 h and presumed to be caused by brain ischemia at the time of referral) within 48 h of symptoms onset.
You may qualify if:
- Patients with suspected TIA (defined as the acute onset of focal neurological symptoms lasting \<24 h and presumed to be caused by brain ischemia at the time of referral) within 48 h of symptoms onset.
- At least 18 years old.
- Having given their Informed Consent.
You may not qualify if:
- · Patients with ocular TIA (Amaurosis fugax).
- Contraindication to perform MRI.
- For women: pregnancy.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Dr. med. Carlo Ceredalead
- Ente Ospedaliero Cantonale, Bellinzonacollaborator
Study Sites (2)
Centre hospitalier Vaudois
Lausanne, Canton of Vaud, 1011, Switzerland
Ospedale Regionale di Lugano
Lugano, Canton Ticino, 6900, Switzerland
Biospecimen
MiRNA will be isolated from whole blood collected in PAXgene tubes (BD/PreAnalytiX, Franklin Lakes, NJ). PAXgene tubes contain an RNA stabilizing reagent that acts at time of blood draw to prevent RNA degradation. RNA in whole blood is derived mainly from peripheral blood cells (monocytes, neutrophils, T cells, B cells, and megakaryocytes).
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Carlo Cereda, MD
Neurocentro della Svizzera Italiana Ospedale Regionale di Lugano
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER GOV
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- MD Capo Servizio
Study Record Dates
First Submitted
June 19, 2019
First Posted
June 21, 2019
Study Start
August 4, 2017
Primary Completion
December 31, 2020
Study Completion
December 31, 2021
Last Updated
April 18, 2024
Record last verified: 2024-04